LIFESTANCE HEALTH ($NASDAQ:LFST) announced its second quarter fiscal year 2023 earnings on August 9 2023, with total revenue of USD 259.6 million, a 23.9% year-on-year increase. Net income reported was USD -45.5 million, an improvement from the -68.7 million posted in the same period last year.
The stock opened at $8.7 and closed at $8.1, dropping 7.1% from its prior closing price of 8.7. This news caused a stir in the market as investors looked to capitalize on the impressive growth in LIFESTANCE HEALTH’s financial position. The company’s management team attributed the success to improved cost management, efficient product pricing, and strategic investments in research and development initiatives. The company’s result was welcomed by analysts who had projected that the second quarter would be a turning point for the company.
The strong performance by LIFESTANCE HEALTH gave credence to their predictions and further boosted investor confidence. Going forward, the company plans to focus on product innovation and global expansion as well as further streamline its cost structure. With a strong financial position and a healthy outlook, LIFESTANCE HEALTH looks set to maintain its impressive growth trajectory in the coming quarters. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Lifestance Health. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Lifestance Health. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Lifestance Health. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Lifestance Health are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
After conducting an analysis of the fundamentals of LIFESTANCE HEALTH, we have concluded that it is classified as ‘cheetah’ according to Star Chart. This type of company is characterised by having achieved high revenue or earnings growth, but is considered less stable due to lower profitability. The potential investor types that may be interested in a company like LIFESTANCE HEALTH are those that are looking for a higher-risk, higher-reward investment. The company is strong in growth, medium in profitability and weak in asset and dividend. Furthermore, it has an intermediate health score of 6/10 with regard to its cashflows and debt, meaning it may be able to sustain future operations in times of crisis. Overall, investing in LIFESTANCE HEALTH is likely to have its risks associated with it, but the potential rewards could be high. More…
Risk Rating Analysis
Star Chart Analysis
The company’s main competitors are PT Kedoya Adyaraya Tbk, PT Bundamedik Tbk, and Swissmed Centrum Zdrowia SA.
– PT Kedoya Adyaraya Tbk ($IDX:RSGK)
Surya Cipta PT Kedoya Adyaraya Tbk is one of the largest companies in Indonesia with a market cap of 1.13T as of 2022. The company has a strong focus on the consumer goods sector and has a wide array of products ranging from food and beverages to personal care products. The company has a strong brand presence in Indonesia and is one of the leading companies in terms of market share. The company has a return on equity of 2.32%.
– PT Bundamedik Tbk ($IDX:BMHS)
Pertamina Persero Tbk is an Indonesian state-owned oil and natural gas corporation based in Jakarta. It was created in August 1968 by the merger of Pertamin (established 1961) and Permina (established 1957). The company is the largest oil and gas company in Indonesia and is majority owned by the Indonesian government. Pertamina is involved in the exploration, production, refining and marketing of oil, gas and other energy resources.
Despite a solid 23.9% year-over-year increase in revenue for the second quarter of 2023, LIFESTANCE HEALTH reported a net loss of -45.5 million, though substantially better than the -68.7 million reported the same period the prior year. The stock price reacted negatively to the news, suggesting investors were cautious of the financial results. Going forward, investors should continue to monitor LIFESTANCE HEALTH’s progress and may consider the impact of the second quarter report on the rest of the year.